European Society of Cardiology (ESC) Congress 2022
Barcelona, Spain 26 August 2022 - 29 September 2022
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
23 Oct 2022
Antihypertensive dosing TIME does not affect CV outcomes
Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.
Antihypertensive dosing TIME does not affect CV outcomes
26 Sep 2022
DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults
Older adults who receive a high-dose quadrivalent influenza vaccine have a 49 percent reduced risk of death and a 64 percent reduced risk of hospitalization for influenza or pneumonia compared with those who receive a standard-dose vaccine, results of the DANFLU-1 study showed.
DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults
22 Sep 2022
Polypill strategy triumphs in reducing MACE post-MI
A polypill comprising aspirin, ramipril, and atorvastatin, significantly reduced the incidence of major adverse cardiovascular (CV) events in patents with a recent myocardial infarction (MI), according to results of a phase III trial presented at ESC 2022.